Department of Medicine, Cardiovascular Division, School of Medicine & Public Health, University of Wisconsin-Madison, 600 Highland Avenue, E5/582; MC 5710, Madison, WI, 53792, USA.
Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Cardiovasc Drugs Ther. 2021 Feb;35(1):33-40. doi: 10.1007/s10557-020-07092-9. Epub 2020 Oct 19.
It remains unclear if use of amiodarone pre-cardiac transplantation impacts early post-transplant survival.
We selected all patients undergoing heart transplant from 2004 to 2006 with available information using the United Network for Organ Sharing database (n = 4057). Multivariable Cox models compared the risk of death within 30 days post-transplant in patients who were taking amiodarone at the time of transplant listing (n = 1227) to those who were not (n = 2830).
Mean age was 52 (± 12) years, and 23% were women. Patients who died within 30 days (n = 168) were older; had higher panel reactive antibody levels, higher bilirubin levels, and higher prevalence of prior cardiac surgery; were often at status 1B; and had higher use of amiodarone at listing compared to those who survived (5.3% versus 3.6%; p = 0.02). Cause of death was unknown in 49% and was reported as graft failure in 43% of cases. In multivariable Cox models, patients on amiodarone at the time of listing had 1.56-fold higher risk of post-transplant death within 30 days (95% confidence intervals 1.08-2.27) compared to patients who were not on amiodarone at listing (C-statistic 0.70).
In conclusion, patients who reported taking amiodarone at the time of listing for transplant had a higher risk of death within 30 days post-transplant.
心脏移植前使用胺碘酮是否会影响移植后的早期存活率仍不清楚。
我们使用器官共享联合网络(United Network for Organ Sharing,UNOS)数据库,选择了 2004 年至 2006 年期间所有有可用信息的接受心脏移植的患者(n=4057)。多变量 Cox 模型比较了在移植名单上服用胺碘酮的患者(n=1227)与未服用胺碘酮的患者(n=2830)在移植后 30 天内死亡的风险。
平均年龄为 52(±12)岁,23%为女性。30 天内死亡的患者(n=168)年龄较大; panels 反应性抗体水平、胆红素水平和先前心脏手术的发生率较高;通常处于 1B 状态;在名单上列出时,胺碘酮的使用率高于存活患者(5.3%比 3.6%;p=0.02)。49%的死亡原因未知,43%的死亡原因报告为移植物衰竭。在多变量 Cox 模型中,与未在名单上使用胺碘酮的患者相比,在名单上列出时使用胺碘酮的患者在移植后 30 天内死亡的风险增加了 1.56 倍(95%置信区间 1.08-2.27)(C 统计量 0.70)。
总之,在名单上列出时报告服用胺碘酮的患者在移植后 30 天内死亡的风险更高。